Traditional myocardial injury markers, including cardiac troponin I (cTnI) and creatine phosphokinase-isoenzyme-MB (CK-MB), present limitations for the diagnosis of early AMI, such as their low sensitivity and short detection window. Early diagnosis and identification of AMI in patients with chest pain, as well as the rapid restoration of blood perfusion to the vessel responsible for the infarct are keys to saving the lives of AMI patients and improving prognosis. With the increased aging of the population, AMI has become one of the main causes of sudden death in middle-aged and elderly people, and it has been reported that about 8 million people die from AMI every year ( 2). The disease often progresses rapidly and has many complications, and the mortality rate is extremely high ( 1). Accepted for publication Jan 31, 2021.Īcute myocardial infarction (AMI) has a sudden onset, with severe and long-lasting posterior sternal pain as the main clinical symptom. Keywords: Acute myocardial infarction (AMI) dimethylglycine (DMG) human maternally expressed gene 3 (MEG3) Apelin-12 Among them, MEG3 was the most effective in early diagnosing AMI. Using 0.015 as the cut-off value for MEG3-messenger ribonucleic acid (mRNA), the sensitivity and specificity for diagnosing AMI were 85.29% and 81.58%, respectively.Ĭonclusions: Our results showed that the plasma levels of DMG, MEG3, and Apelin-12 in patients with AMI were high, and thus, they can be used as biomarkers for the early diagnosis of AMI. The area under the curve (AUC) of MEG3 was higher than that of both DMG and Apelin-12, however the difference was not statistically significant (Z=1.378, 0.934, P=0.168, 0.350). The plasma DMG, MEG3, and Apelin-12 levels of patients in the AMI group on admission were higher than those of the non-AMI group (P<0.05) all have diagnostic value for AMI upon admission. The proportions of systolic blood pressure (SBP), ST-segment elevation, and electrocardiogram (ECG) dynamic changes on admission were also higher in the AMI group compared to those of the non-AMI group (P<0.05). The proportion of males, smoking, history of myocardial infarction, and congestive heart failure in the AMI group were higher than those of the non-AMI group. Results: Among the 110 patients with chest pain suspected of AMI, 34 were clinically diagnosed with AMI, and 76 were non-AMI patients. The receiver operating characteristic (ROC) curve was used to analyze the clinical value of plasma DMG, MEG3, and Apelin-12 levels for the early diagnosis of AMI. The levels of plasma DMG, MEG3, and Apelin-12, as well as the general data and admission baseline data of these patients were then compared with those of non-AMI patients. Plasma DMG, MEG3, and Apelin-12 levels were measured at the time of admission. Methods: One hundred and ten patients with suspected AMI (chest pain duration <6 h) who were admitted to our hospital between December 2018 and June 2020 were included.
Background: To analyze the expression levels of plasma dimethylglycine (DMG), human maternally expressed gene 3 (MEG3), and Apelin-12 in patients with acute myocardial infarction (AMI) and explore their clinical significance.
0 kommentar(er)
